Short Interest in Catheter Precision, Inc. (NYSEAMERICAN:VTAK) Increases By 217.0%

Catheter Precision, Inc. (NYSEAMERICAN:VTAK) saw a large growth in short interest during the month of August. As of August 31st, there was short interest totaling 398,714 shares, a growth of 217.0% from the August 15th total of 125,762 shares. Based on an average trading volume of 3,391,068 shares, the short-interest ratio is presently 0.1 days. Currently, 2.9% of the shares of the stock are short sold.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in Catheter Precision stock. Millennium Management LLC bought a new stake in Catheter Precision, Inc. (NYSEAMERICAN:VTAK) in the 4th quarter, according to its most recent 13F filing with the SEC. The firm bought 34,721 shares of the company’s stock, valued at approximately $64,000. Millennium Management LLC owned 2.08% of Catheter Precision at the end of the most recent reporting period. 20.34% of the stock is owned by institutional investors and hedge funds.

Catheter Precision Price Performance

VTAK stock traded up $0.01 during midday trading on Friday, reaching $0.17. 712,209 shares of the stock were exchanged, compared to its average volume of 2,238,078. The stock has a market capitalization of $2.52 million, a PE ratio of -0.03 and a beta of -1.03. Catheter Precision has a 52 week low of $0.16 and a 52 week high of $3.20. The company has a debt-to-equity ratio of 0.19, a current ratio of 0.19 and a quick ratio of 0.18. The company has a fifty day moving average price of $0.36 and a 200 day moving average price of $0.82.

Catheter Precision (NYSEAMERICAN:VTAK) last posted its earnings results on Friday, August 14th. The company reported ($0.92) EPS for the quarter, beating the consensus estimate of ($19.00) by $18.08. Catheter Precision had a negative return on equity of 37.53% and a negative net margin of 656.03%.The firm had revenue of $1.02 million during the quarter, compared to the consensus estimate of $2.00 million.

About Catheter Precision

Catheter Precision, Inc (NYSE American: VTAK) is a medical device company specializing in the design, development and manufacture of catheter-based products for interventional cardiology and peripheral vascular procedures. The company’s core business centers on balloon catheter platforms, offering both standard and specialty catheter configurations that address applications ranging from percutaneous transluminal angioplasty (PTA) to percutaneous transluminal coronary angioplasty (PTCA). Catheter Precision’s product portfolio is engineered to meet diverse clinical needs, including high-pressure dilation, scored and cutting balloon therapies, and drug-coated balloon delivery.

All of Catheter Precision’s products are developed in its ISO 13485-certified, FDA-registered manufacturing facility in Bloomington, Minnesota.